Mabwell (Shanghai) Bioscience Co., Ltd. (2493.HK)

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.